Christopher T. Chan, MD|
Director Division of Nephrology
University Health Network
R Fraser Elliot Chair in Home Dialysis
Professor of Medicine
University of Toronto, Canada
Brent W. Miller, MD
Professor of Medicine
Washington University School of Medicine &
Director, Dialysis Home Modali1es
Barnes-Jewish Hospital Dialysis Center
St. Louis, Missouri
Elizabeth Lindley, PhD
Clinical Scientist in Renal Care
Department of Renal Medicine
St. James's University Hospital
Leeds, United Kingdom
William Whitter, MD
Associate Professor of Medicine, Nephrology
Rush University Medical Center, Chicago, IL
Medical Director for Home Dialysis and
Nursing Home Dialysis
Circle Medical Management, Chicago, IL
Medical Director for NxStage Kidney Care
Oak Brook, Illinois
The live program on which this Web-based educational activity is based was supported by educational grants from Fresenius Medical Care, Dialysis Centers Inc, Baxter Healthcare, and Amgen. No industry funding was provided for support of the Web-based program.
This program will discuss on clinically important problems in dialysis, including home hemodialysis (prescription and delivery), complexities of anemia management, pathogenesis and implications of newly recognized unique complications of hemodialysis, and the value of reporting and analysis of patient reported outcomes in improving quality of hemodialysis.
The program is also aimed at improving the overall level of hemodialysis, and provide a good platform for learning and engage in international exchanges hemodialysis doctors, nurses and engineers.
Upon completion of this activity, the participants should be able to:
- HOME HEMODIALYSIS: Describe methods used to select and train patients for home hemodialysis, manage vascular access, home modification for home hemodialysis, equipment maintenance, remote monitoring, adequacy, and patient safety.
- ANEMIA: Discuss best practices regarding management of anemia in hemodialysis patients including indications for transfusions, hemoglobin targets, iron use, and anemia management algorithms.
- Assess how to recognize the “DARK SIDE OF HEMODIALYSIS”, i.e. hemodialysis complications like myocardial and brain stunning, individualized dialysate temperature and cool dialysate.
- Evaluate ANALYTICAL TECHNIQUES for reporting patient reported outcomes.
This program is designed for health professionals involved in dialysis programs, primarily nephrologists, nephrology fellows, nephrology nurses and nurse practitioners, and patient care technicians.
Physician and Nursing Credit
| ACCREDITATION AND DESIGNATION STATEMENTS:
Although the live programs were prepared under CME accreditation guidelines, no CME/CE credit is available for participating in this Web-archived activity.
| SPEAKER DISCLOSURE STATEMENT and OFF-LABEL USE:
Each speaker has
completed and signed a conflict of interest statement. The faculty members' relationship will be
disclosed in the course materials.
Christopher T. Chan, MD, receives consulting fees from Baxter Global and Intelomed.
Brent Miller, MD, receives grants/research support from NxStage Medical; consultng fees from Fresenius Medical and NxStage Medical; a salary from Washington
University; and is a shareholder in Fresenius Medical Care.
Elizabeth Lindley, PhD, has no financial relationship to disclose.
William Whitter, MD, receives a salary as Medical Director for NxStage Kidney
Please refer to the official prescribing information for each product for discussion of approved indications,
contraindications, and warnings. Further, participants should appraise the information presented critically and are
encouraged to consult appropriate resources for any product or device mentioned in this program. The information presented
at this program represents the views and opinions of the individual presenters, and does not constitute the opinion or
endorsement of, or promotion by, HDCN or the ISHD. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Before prescribing any medicine, primary references and full prescribing information should be consulted.
The policy statements of HDCN are listed on this page.